8-K: Innovative MedTech Secures $85,000 Convertible Note

Innovative MedTech enters into a securities purchase agreement for a $85,000 convertible note to fund business development and working capital.

Summary

• Innovative MedTech, Inc. entered into a securities purchase agreement with Labrys Fund II, L.P. on August 6, 2025.
• The company sold a convertible promissory note with a principal amount of $97,750 to Labrys for a purchase price of $85,000.
• Labrys retained $3,500 for legal fees and paid $4,500 to HCC Securities Group, Inc., resulting in net funding of $77,000 to the company.
• The note matures in twelve months and accrues a one-time interest charge of 12% at issuance.
• The company shall pay $54,740 by February 4, 2026, and $9,123.33 by the 4th day of each month thereafter.
• The note is convertible into common stock at 71% of the lowest closing bid price during the 10 trading days prior to conversion, subject to beneficial ownership limitations.
• The holder can deduct $1,500 from the conversion amount for conversion-related fees.

Sentiment

Score: 4

Explanation: The announcement is neutral to slightly negative. While securing funding is positive, the terms of the convertible note, including the high interest rate and potential dilution, are concerning.

Positives

• The funding will be used for business development and general working capital purposes.
• The company has secured $77,000 in net funding after fees.
• The agreement includes customary representations, warranties, and covenants.

Negatives

• The company is restricted from using the proceeds to repay debt owed to officers, directors, or employees, debt from corporate finance transactions, or for loans/investments in other entities or affiliates.
• The note includes a one-time interest charge of 12% on the principal amount at issuance.
• The note is convertible at a discount of 71% of the lowest closing bid price, which could lead to significant dilution.
• The holder is entitled to deduct $1,500 from the conversion amount in each note conversion to cover the holders fees associated with the conversion.

Risks

• The conversion of the note could result in dilution of the Companys common stock.
• The company's failure to comply with the terms of the agreement or the note could result in an event of default, leading to accelerated payment obligations.
• The company is subject to various covenants that restrict its activities, such as changing the nature of its business or selling material assets without the buyer's consent.
• The company's failure to maintain its listing on the Principal Market could trigger an event of default.
• The company's failure to comply with the reporting requirements of the 1934 Act could trigger an event of default.
• The company's failure to pay an Amortization Payment within five calendar days of the due date could trigger an event of default.

Future Outlook

The company intends to use the proceeds from the transaction for business development and general working capital purposes.

Management Comments

• No specific management comments were included in the filing.

Industry Context

This type of financing is common for small companies to raise capital. Convertible notes are often used as a bridge to future equity financing rounds.

Comparison to Industry Standards

• Comparable companies in the biotech industry, such as [Placeholder Company A] and [Placeholder Company B], have also utilized convertible notes for early-stage funding.
• The terms of the note, including the interest rate and conversion discount, are within the typical range for similar transactions in the microcap market.
• The use of proceeds for business development and working capital is a standard practice for companies at this stage of development.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• Employees may benefit from the funding being used for business development and working capital.
• The company's ability to execute its business plan may be enhanced by the funding.

Next Steps

• The company will use the funding for business development and general working capital.
• The company will make amortization payments on the note as scheduled.
• The holder may elect to convert the note into common stock.

Key Dates

Recommendation

The terms of the convertible note are unfavorable, with a high interest rate and significant potential dilution. The restrictions on the use of proceeds and the various covenants also raise concerns. A seasoned investor would likely view this as a negative development and consider selling the stock.

Keywords

convertible note, securities purchase agreement, funding, Labrys Fund II, Innovative MedTech, business development, working capital, common stock, conversion, dilution